查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2085178

良性前列腺增生治療市場：依療法、產品類型、最終用戶和分銷管道分類－2026-2032年全球市場預測

Benign Prostatic Hyperplasia Treatment Market by Treatment Type, Product Type, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，良性前列腺增生 (BPH) 治療市場將成長至 139.6 億美元，複合年成長率為 6.12%。

主要市場統計數據
基準年 2025 92億美元
預計年份：2026年 97.4億美元
預測年份 2032 139.6億美元
複合年成長率 (%) 6.12%

良性攝護腺增生（BPH）的治療已從廣泛的症狀管理發展到針對老年男性下泌尿道症狀的個人化、風險分層管理。 BPH的盛行率老齡化成長而急劇上升，美國泌尿系統協會（AUA）、歐洲泌尿系統與臨床最佳化研究所（NICE）的臨床指南推薦分階段治療方案，包括後續觀察、生活方式調整、α受體阻斷劑、5α還原酶抑制劑、聯合治療、微創手術和根治性手術。

市場成長動力源自於全球人口老化、診斷率上升、遠距泌尿系統醫療的普及，以及患者對能夠保留性功能並減少導尿、住院和復健時間的治療方案的偏好。與競爭對手的差異化競爭越來越依賴真實世界數據，這些數據能夠證明治療方案的臨床持久性、安全性、醫保報銷、醫生培訓以及在不同前列腺大小、解剖結構、合併症和用藥史等因素下的治療效果。

良性攝護腺增生症治療前景的變革性變化

良性前列腺增生（BPH）的治療模式正在發生變化，微創手術療法，例如前列腺尿道提升術、蒸氣療法、暫時性前列腺植入、水磨術和栓塞術，拓展了長期藥物治療和傳統手術之間的選擇。雖然這些療法滿足了患者更快康復和減少對性功能副作用的需求，但對於前列腺明顯閉尿症、尿瀦留和嚴重梗阻的病例，經尿道前列腺切除術、雷射剜除術和其他根治性手術仍然十分重要。

人工智慧對良性前列腺增生症治療的累積影響

人工智慧 (AI) 正透過影像診斷、症狀評分、工作流程自動化、臨床決策支援和預測分析等方式，開始影響良性前列腺增生 (BPH) 的治療。當人工智慧工具與經過驗證的臨床數據和醫生監督相結合時，可以幫助泌尿系統檢驗前列腺體積、膀胱出口阻塞風險、藥物治療反應可能性以及術後併發症。

關鍵區域洞察：區域對良性前列腺增生症治療的需求

亞太地區良性前列腺增生症（BPH）治療市場正經歷高速成長，這主要得益於中國、日本、韓國和澳洲人口的快速老化，以及印度和東協市場專科醫生數量的不斷增加。日本是全球老化程度最高的國家之一，而中國和韓國的老年男性人口也在持續成長，這增加了對診斷評估、慢性病治療和微創療法的需求。北美地區仍然是泌尿系統和醫療保險報銷的重要中心，這得益於該地區泌尿外科手術量大、美國符合醫療保險資格的老年群體的需求、對微創技術的積極應用以及完善的、以指南為基礎的醫療保健體系。

東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約的關鍵集團分析

東協市場的特點是診斷率上升、醫療旅遊路線發展以及私人醫院網路不斷擴張，這為經濟實惠的藥物和可大規模擴充性的微創良性前列腺增生（BPH）治療方案創造了商機。海灣合作理事會（GCC）國家正在投資三級醫療、機器人手術基礎設施和國際臨床合作，推動高所得患者和外籍人士群體採用先進的泌尿系統平台。

重點國家洞察：良性前列腺增生 (BPH) 治療的首選市場

美國是良性前列腺增生（BPH）治療領域領先的創新市場，這得益於其強大的泌尿系統專家網路、符合聯邦醫療保險（Medicare）資格的各年齡層人群的需求，以及種類繁多的微創和外科治療方案。加拿大透過公共資助途徑和配套的私人服務，保持穩定的需求。同時，墨西哥和巴西在擴大中產階級醫療保健覆蓋範圍的同時，也面臨大規模人口在診斷和治療方面仍未得到充分服務的問題。在歐洲，英國、德國、法國、義大利和西班牙強調以指引為基礎的醫療保健、實證報銷、臨床效率和治療品質。俄羅斯雖然面臨老齡化男性人口的需求，但也面臨醫療保健可近性、經濟負擔和供應鏈不穩定等挑戰。

為良性前列腺增生症治療行業的領導者提供的實用建議

產業領導者應優先考慮差異化的臨床證據，比較不同治療方法在症狀改善、尿流率、再治療率、性功能維持、不利事件、導尿管依賴性和恢復時間的差異。證據包的設計應面向泌尿系統、保險公司、採購委員會和患者，並應利用真實世界臨床註冊研究來補充主要臨床試驗的結果。

調查方法

本執行摘要基於二手研究，資訊來源了權威的臨床和公共衛生資源，包括泌尿系統指南、同行評審文獻、監管動態、醫院實踐趨勢、人口統計和報銷框架。證據的臨床相關性已根據其與良性前列腺增生症（BPH）治療路徑（包括藥物治療、微創介入治療和外科手術治療）的關聯性進行了評估。

結論

眼瞼成形術（良性前列腺增生）的治療正朝著更個人化、微創和數據驅動的方向發展。隨著人口老化、患者期望值不斷提高以及治療選擇的日益增多，人們越來越需要能夠縮短恢復時間、維持生活品質並改善泌尿系統症狀的解決方案。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：良性攝護腺增生症治療市場：依治療類型分類

  • 製藥
    • 5α-還原酶抑制劑
    • α受體阻斷劑
  • 微創治療
    • 攝護腺動脈栓塞術
    • 蒸氣療法
  • 手術治療
    • 雷射手術
    • 前列腺尿道提升術
    • 經尿道前列腺切開術
    • 經尿道前列腺切除術

第8章 良性攝護腺增生治療市場：依產品類型分類

  • 導管
  • 電極
  • 植入
  • 攝護腺支架
  • 電切鏡
  • 泌尿系統雷射

第9章：良性攝護腺增生治療市場：依最終使用者分類

  • 門診手術中心
  • 診所
  • 居家照護
  • 醫院

第10章：良性攝護腺增生治療市場：依通路分類

  • 離線
  • 線上

第11章：良性攝護腺增生治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章：良性攝護腺增生治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章：良性攝護腺增生治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • AbbVie Inc.
  • Alembic Pharmaceuticals Limited
  • Asahi Kasei Corporation
  • Astellas Pharma Inc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Boston Scientific Corporation
  • Cipla Ltd.
  • Coloplast Group
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • Endo International PLC
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • IPG Photonics Corporation
  • Lumenis Ltd.
  • Olympus Corporation
  • Organon group of companies
  • PROCEPT BioRobotics Corporation
  • ProstaLund AB
  • Quanta System
  • Richard Wolf GmbH
  • Teleflex Incorporated
  • Urologix, LLC.
Product Code: MRR-437D4595848A

The Benign Prostatic Hyperplasia Treatment Market is projected to grow by USD 13.96 billion at a CAGR of 6.12% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.20 billion
Estimated Year [2026] USD 9.74 billion
Forecast Year [2032] USD 13.96 billion
CAGR (%) 6.12%

Benign prostatic hyperplasia (BPH) treatment is evolving from broad symptom control toward personalized, risk-stratified management of lower urinary tract symptoms in aging men. BPH prevalence rises sharply with age, and clinical guidance from the American Urological Association (AUA), European Association of Urology (EAU), and NICE supports a stepped pathway that includes watchful waiting, lifestyle modification, alpha blockers, 5-alpha-reductase inhibitors, combination therapy, minimally invasive surgical therapies, and definitive procedures.

Market momentum is supported by global demographic aging, higher diagnosis rates, tele-urology adoption, and patient preference for therapies that preserve sexual function and reduce catheterization, hospitalization, and recovery time. Competitive differentiation increasingly depends on clinical durability, safety, reimbursement access, physician training, and real-world evidence demonstrating outcomes across prostate size, anatomy, comorbidity, and medication history.

Transformative Shifts in the BPH Treatment Landscape

The BPH treatment landscape is shifting as minimally invasive surgical therapies, including prostatic urethral lift, water vapor thermal therapy, temporary implanted prostatic devices, aquablation, and embolization approaches, expand options between long-term medication and traditional surgery. These therapies address demand for faster recovery and lower sexual side-effect burden, while transurethral resection of the prostate, laser enucleation, and other definitive interventions remain important for larger glands, urinary retention, and severe obstruction.

Pharmaceutical strategies are also changing. Alpha blockers remain widely used for rapid symptom relief, while 5-alpha-reductase inhibitors are prioritized for enlarged prostates and disease progression risk. Combination therapy, medication adherence support, and shared decision-making are increasingly central as clinicians balance symptom improvement, adverse effects, cost, and long-term retreatment risk.

Cumulative Impact of Artificial Intelligence on BPH Care

Artificial intelligence is beginning to influence BPH care through imaging interpretation, symptom scoring, workflow automation, clinical decision support, and predictive analytics. AI-enabled tools can help urologists evaluate prostate volume, bladder outlet obstruction risk, medication response probability, and post-procedure complications when integrated with validated clinical data and physician oversight.

The cumulative impact is most visible in care pathway efficiency. Digital intake, remote monitoring, natural-language processing of clinical notes, and AI-assisted triage can reduce delays from symptom onset to specialist evaluation. However, adoption depends on transparent algorithms, bias monitoring, cybersecurity, regulatory compliance, and validation across diverse populations because BPH outcomes vary by age, anatomy, comorbidities, and access to urologic care.

Key Regional Insights: BPH Treatment Demand by Geography

Asia-Pacific is a high-growth region for BPH treatment due to rapid aging in China, Japan, South Korea, and Australia, combined with expanding specialist capacity in India and ASEAN markets. Japan is among the world's oldest societies, and China and South Korea are experiencing sustained growth in older male populations, strengthening demand for diagnostic evaluation, chronic medication, and minimally invasive treatment. North America remains a major innovation and reimbursement hub, supported by high urology procedure volumes, Medicare-aged demand in the United States, strong adoption of minimally invasive technologies, and established guideline-based care.

Europe benefits from structured health technology assessment, broad clinical guideline alignment, and mature urology service networks, particularly across the European Union and the United Kingdom. Latin America shows rising demand as Brazil and Mexico expand private healthcare access and urban specialty care capacity, although affordability and uneven access continue to affect treatment uptake. The Middle East, led by GCC investment in specialty hospitals and tertiary care, is increasing access to advanced urologic procedures. Africa remains more uneven, with BPH treatment access linked to urban hospital investment, workforce development, diagnostic availability, and improved access to essential urology services.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are characterized by rising diagnosis, medical tourism corridors, and expanding private hospital networks, creating opportunities for cost-effective medications and scalable minimally invasive BPH procedures. GCC countries are investing in tertiary care, robotic surgery infrastructure, and international clinical partnerships, supporting adoption of advanced urology platforms among high-income patient populations and expatriate communities.

The European Union emphasizes evidence, safety, procurement value, and reimbursement discipline, favoring BPH treatment products supported by comparative outcomes and durable data. BRICS countries represent substantial long-term clinical need due to large aging male populations, but access, pricing, hospital infrastructure, and reimbursement vary widely across member economies. G7 markets generally lead in technology adoption, clinical trial activity, and guideline implementation, while NATO-aligned systems outside the G7 often follow European and North American standards for training, quality, device regulation, and health system readiness.

Key Country Insights: Priority BPH Treatment Markets

The United States is a leading environment for BPH treatment innovation, supported by specialty urology networks, Medicare-aged demand, and availability of minimally invasive and surgical options. Canada shows steady demand through publicly funded pathways and private adjunct services, while Mexico and Brazil combine expanding middle-class healthcare access with large populations that remain underdiagnosed or undertreated. In Europe, the United Kingdom, Germany, France, Italy, and Spain emphasize guideline-based care, reimbursement evidence, clinical efficiency, and procedure quality; Russia maintains demand from an aging male population but faces access, affordability, and supply-chain variability.

China and India represent major long-term opportunities because of aging demographics, improving diagnostic penetration, and expanding hospital capacity, although affordability and hospital tier differences shape uptake. Japan and South Korea support advanced procedural adoption due to aging populations, sophisticated health systems, and high expectations for functional outcomes. Australia shows strong alignment with evidence-based urology practice and private-sector access to newer procedures, reinforcing demand for therapies that reduce recovery time and preserve quality of life.

Actionable Recommendations for BPH Treatment Industry Leaders

Industry leaders should prioritize differentiated clinical evidence that compares symptom improvement, urinary flow, retreatment rates, sexual function preservation, adverse events, catheter dependence, and recovery time across therapies. Evidence packages should be designed for urologists, payers, procurement committees, and patients, with real-world registries strengthening claims beyond pivotal trials.

Commercial execution should combine physician education, patient decision aids, reimbursement strategy, and service-line partnerships with high-volume urology centers. Organizations should localize pricing, training, and distribution models for emerging markets while maintaining regulatory quality. Digital symptom tracking, AI-assisted care navigation, and post-procedure monitoring can improve adherence, patient satisfaction, and longitudinal outcome measurement.

Research Methodology

This executive summary is grounded in secondary research from recognized clinical and public health sources, including urology guidelines, peer-reviewed literature, regulatory updates, hospital practice trends, demographic data, and reimbursement frameworks. Evidence was assessed for clinical relevance to BPH treatment pathways, including pharmacologic therapy, minimally invasive interventions, and surgical management.

The methodology emphasizes triangulation across guideline recommendations, epidemiology, technology adoption signals, and regional healthcare access indicators. Insights were structured to support strategic planning, market prioritization, executive communication, and decision-making for stakeholders across medical devices, pharmaceuticals, digital health, provider organizations, and healthcare investors.

Conclusion

BPH treatment is moving toward more personalized, less invasive, and data-enabled care. Aging populations, rising patient expectations, and expanding procedure portfolios are increasing demand for solutions that improve urinary symptoms while limiting recovery time and preserving quality of life.

The strongest opportunities will favor organizations that combine durable clinical outcomes, physician training, patient-centered education, payer-ready evidence, and responsible digital innovation. As AI, minimally invasive therapies, and regional healthcare investment converge, the BPH treatment landscape is positioned for sustained transformation across developed and emerging health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Benign Prostatic Hyperplasia Treatment Market, by Treatment Type

  • 7.1. Medications
    • 7.1.1. 5-Alpha-Reductase Inhibitors
    • 7.1.2. Alpha Blockers
  • 7.2. Minimally Invasive Therapies
    • 7.2.1. Prostate Artery Embolization
    • 7.2.2. Water Vapour Therapy
  • 7.3. Surgical Treatments
    • 7.3.1. Laser Surgery
    • 7.3.2. Prostatic Urethral Lift
    • 7.3.3. Transurethral Incision Of The Prostate
    • 7.3.4. Transurethral Resection Of The Prostate

8. Benign Prostatic Hyperplasia Treatment Market, by Product Type

  • 8.1. Catheters
  • 8.2. Electrodes
  • 8.3. Implants
  • 8.4. Prostatic Stents
  • 8.5. Resectoscopes
  • 8.6. Urology Laser

9. Benign Prostatic Hyperplasia Treatment Market, by End User

  • 9.1. Ambulatory Surgical Centers
  • 9.2. Clinics
  • 9.3. Homecare
  • 9.4. Hospitals

10. Benign Prostatic Hyperplasia Treatment Market, by Distribution Channel

  • 10.1. Offline
  • 10.2. Online

11. Benign Prostatic Hyperplasia Treatment Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. Benign Prostatic Hyperplasia Treatment Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Benign Prostatic Hyperplasia Treatment Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Concentration Analysis, 2025
    • 14.1.1. Concentration Ratio (CR)
    • 14.1.2. Herfindahl Hirschman Index (HHI)
  • 14.2. Recent Developments & Impact Analysis, 2025
  • 14.3. Product Portfolio Analysis, 2025
  • 14.4. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. AbbVie Inc.
  • 15.2. Alembic Pharmaceuticals Limited
  • 15.3. Asahi Kasei Corporation
  • 15.4. Astellas Pharma Inc.
  • 15.5. Bayer AG
  • 15.6. Boehringer Ingelheim GmbH
  • 15.7. Boston Scientific Corporation
  • 15.8. Cipla Ltd.
  • 15.9. Coloplast Group
  • 15.10. Dr. Reddy's Laboratories
  • 15.11. Eli Lilly and Company
  • 15.12. Endo International PLC
  • 15.13. GlaxoSmithKline plc
  • 15.14. Hikma Pharmaceuticals PLC
  • 15.15. IPG Photonics Corporation
  • 15.16. Lumenis Ltd.
  • 15.17. Olympus Corporation
  • 15.18. Organon group of companies
  • 15.19. PROCEPT BioRobotics Corporation
  • 15.20. ProstaLund AB
  • 15.21. Quanta System
  • 15.22. Richard Wolf GmbH
  • 15.23. Teleflex Incorporated
  • 15.24. Urologix, LLC.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MEDICATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MEDICATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL 5-ALPHA-REDUCTASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL 5-ALPHA-REDUCTASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL 5-ALPHA-REDUCTASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ALPHA BLOCKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ALPHA BLOCKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ALPHA BLOCKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MINIMALLY INVASIVE THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MINIMALLY INVASIVE THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MINIMALLY INVASIVE THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PROSTATE ARTERY EMBOLIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PROSTATE ARTERY EMBOLIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PROSTATE ARTERY EMBOLIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL WATER VAPOUR THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL WATER VAPOUR THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL WATER VAPOUR THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SURGICAL TREATMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SURGICAL TREATMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SURGICAL TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LASER SURGERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LASER SURGERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LASER SURGERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PROSTATIC URETHRAL LIFT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PROSTATIC URETHRAL LIFT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PROSTATIC URETHRAL LIFT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TRANSURETHRAL INCISION OF THE PROSTATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TRANSURETHRAL INCISION OF THE PROSTATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TRANSURETHRAL INCISION OF THE PROSTATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TRANSURETHRAL RESECTION OF THE PROSTATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TRANSURETHRAL RESECTION OF THE PROSTATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TRANSURETHRAL RESECTION OF THE PROSTATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CATHETERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CATHETERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CATHETERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ELECTRODES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ELECTRODES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ELECTRODES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IMPLANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IMPLANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PROSTATIC STENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PROSTATIC STENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PROSTATIC STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RESECTOSCOPES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RESECTOSCOPES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RESECTOSCOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL UROLOGY LASER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL UROLOGY LASER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL UROLOGY LASER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HOMECARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HOMECARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HOMECARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. GCC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. GCC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. GCC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 136. GCC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 137. GCC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 138. GCC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. GCC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. GCC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. G7 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. G7 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. G7 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 160. G7 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 161. G7 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 162. G7 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. G7 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. G7 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. NATO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 166. NATO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. NATO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 168. NATO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 169. NATO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 170. NATO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. NATO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. NATO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 183. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 185. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 186. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 187. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 190. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 193. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 194. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 195. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. MEXICO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 201. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 202. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 203. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. BRAZIL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 217. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 218. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 219. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 223. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 225. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 226. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 227. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 231. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 233. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 234. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 235. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. RUSSIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 238. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 241. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 242. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 243. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 246. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 247. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 249. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 250. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 251. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 262. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 265. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 266. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 267. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 269. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 270. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 271. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 273. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 274. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 275. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 277. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 278. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 279. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 281. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 282. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 283. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 285. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 286. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 287. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 289. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 290. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 291. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 293. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)